These multiple positive effects in T cell responses may explain the potent T cell costimulatory activity and antitumor efficacy observed with the anti-GITR DTA-1 Ab in several mouse syngeneic tumor models, including CT26 and MC38 colorectal cancer [35, 39], B16 melanoma [40], C3 cervical cancer [41], and multiple models of glioblastoma [34]. Here, TNFRSF18 is linked to neoplasm.